GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » XWELL Inc (NAS:XWEL) » Definitions » EV-to-EBIT

XWELL (XWEL) EV-to-EBIT : 0.23 (As of May. 13, 2024)


View and export this data going back to 2010. Start your Free Trial

What is XWELL EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, XWELL's Enterprise Value is $-4.34 Mil. XWELL's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-19.16 Mil. Therefore, XWELL's EV-to-EBIT for today is 0.23.

The historical rank and industry rank for XWELL's EV-to-EBIT or its related term are showing as below:

XWEL' s EV-to-EBIT Range Over the Past 10 Years
Min: -222.89   Med: -1.35   Max: 26.79
Current: 0.23

During the past 13 years, the highest EV-to-EBIT of XWELL was 26.79. The lowest was -222.89. And the median was -1.35.

XWEL's EV-to-EBIT is ranked better than
96.15% of 104 companies
in the Medical Diagnostics & Research industry
Industry Median: 21.93 vs XWEL: 0.23

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. XWELL's Enterprise Value for the quarter that ended in Dec. 2023 was $3.29 Mil. XWELL's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-19.16 Mil. XWELL's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -583.25%.


XWELL EV-to-EBIT Historical Data

The historical data trend for XWELL's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

XWELL EV-to-EBIT Chart

XWELL Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.53 -1.62 24.29 -0.41 -0.17

XWELL Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.41 -0.57 -0.20 -0.12 -0.17

Competitive Comparison of XWELL's EV-to-EBIT

For the Diagnostics & Research subindustry, XWELL's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


XWELL's EV-to-EBIT Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, XWELL's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where XWELL's EV-to-EBIT falls into.



XWELL EV-to-EBIT Calculation

XWELL's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=-4.336/-19.163
=0.23

XWELL's current Enterprise Value is $-4.34 Mil.
XWELL's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-19.16 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


XWELL  (NAS:XWEL) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

XWELL's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2023 ) =EBIT / Enterprise Value (Q: Dec. 2023 )
=-19.163/3.2855562
=-583.25 %

XWELL's Enterprise Value for the quarter that ended in Dec. 2023 was $3.29 Mil.
XWELL's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-19.16 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


XWELL EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of XWELL's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


XWELL (XWEL) Business Description

Traded in Other Exchanges
N/A
Address
254 West 31st Street, 11th Floor, New York, NY, USA, 10001
XWELL Inc is a health and wellness holding company. It is an airport retailer of spa services through XpresSpa locations, offering travelers premium spa services, including massage, nail, and skincare, as well as spa and travel products. It operates four reportable operating segments: XpresCheck, XpresSpa, Treat, and HyperPointe. XpresSpa is an airport retailer of wellness services and related products. Treat is a travel health and wellness brand that offers in-airport spa and wellness medical services. XpresCheck provides Covid-19 screening and diagnostic testing in partnership with the CDC. HyperPointe is a digital healthcare and data analytics relationship company.
Executives
Suzanne A. Scrabis officer: Chief Financial Officer C/O XWELL, INC., 254 WEST 31ST STREET, 11TH FLOOR, NEW YORK NY 10001
Robert Weinstein director 3960 HOWARD HUGHES PARKWAY, SUITE 500, LAS VEGAS NV 89169
Scott R Milford officer: Chief Executive Officer C/O TOWN SPORTS INTERNATIONAL, LLC, 5 PENN PLAZA, NEW YORK NY 10001
Bruce Bernstein director 780 THIRD AVENUE, 12TH FLOOR, NEW YORK NY 10017
Ezra Ernst officer: See Remarks C/O XPRESSPA GROUP, INC., 254 WEST 31ST STREET, 11TH FLOOR, NEW YORK NY 10001
Omar Haynes officer: VP Treas & Fi & Interim CFO C/O XPRESSPA GROUP, INC., 254 WEST 31ST STREET, 11TH FLOOR, NEW YORK NY 10001
Doug Satzman director, officer: Chief Executive Officer 780 THIRD AVENUE, 12TH FLOOR, NEW YORK NY 10017
James A. Berry officer: Chief Financial Officer C/O XPRESSPA GROUP, INC., 254 WEST 31ST STREET, 11TH FLOOR, NEW YORK NY 10001
Michael Lebowitz director 780 THIRD AVENUE, 12TH FLOOR, C/O XPRESSPA GROUP, INC., NEW YORK NY 10017
Donald E. Stout director 780 THIRD AVENUE, 15TH FLOOR, NEW YORK NY 10017
Mistral Spa Holdings, Llc 10 percent owner C/O MISTRAL CAPITAL MANAGEMENT, LLC, 650 FIFTH AVENUE, 31ST FLOOR, NEW YORK NY 10019
Mistral Capital Management, Llc 10 percent owner 650 FIFTH AVENUE, 31ST FLOOR, NEW YORK NY 10019
Andrew R Heyer other: Former director and 10% owner 501 MADISON AVENUE, FLOOR 5, NEW YORK NY 10019
Calm.com, Inc. 10 percent owner 140 2ND STREET, THIRD FLOOR, SAN FRANCISCO CA 94105
Edward Jankowski officer: SVP; CEO of XpresSpa C/O FORM HOLDINGS CORP., 780 THIRD AVENUE, 12TH FLOOR, NEW YORK NY 10017